Hologic, Inc. (HOLX - Free Report) recently announced the launch of new Fluent fluid management system in the United States. Per the company, this system is embedded with features that simplify and improvise the fluid management for hysteroscopic procedures.
Fluent Fluid Management System in Detail
Equipped with the FloPak technology, the Fluent system also features a single waste bag design to enable fluid monitoring and controlling it during hysteroscopic procedures. It also works in combination with an extensive range of hysteroscopic devices. Further, the system is also equipped with an integrated MyoSure controller, which makes it a comprehensive fluid management and tissue removal system.
Hologic’s strategy to gain traction in the GYN Surgical segment seems to be aligned with data provided by Prescient & Strategic (P&S) Intelligence. Per the report, the global hysteroscope market is expected to witness a CAGR of 4.5% between 2016 and 2022.
They further believe that increasing female geriatric population, growing uterine cancer cases, rising female infertility incidences, increasing cases with abnormal uterine bleeding and rising customer needs of minimally invasive treatments will fuel the growth of the global hysteroscope market. In view of these encouraging factors, we believe that the company’s development regarding the Fluent system is strategic and it is likely to broaden customer base.
A Glimpse at the GYN Surgical Business
After a dull performance in the preceding two quarters, the GYN Surgical business performed impressively in the fiscal third quarter. Despite decline in NovaSure sales, we are upbeat about the solid quarterly show by MyoSure.
According to Hologic, the recent ordering patterns will continue to help the business improve in the latter half of the current fiscal. New leadership, easier comparisons along with revamped sales and marketing efforts are expected to drive growth. Per management, NovaSure sales have started to stabilize.
Hologic has immense prospects in this business which are worth looking forward to. We are upbeat about the recent commercial launch of MyoSure MANUAL device in the United States. Notably, in addition to MyoSure MANUAL, the Myosure products portfolio comprises MyoSure, MyoSure REACH, MyoSure XL and MyoSure LITE devices.
While MyoSure continues to register solid growth, the company is also pursuing a number of strategies to boost growth in Surgical. Going forward, Hologic expects the surgical business to witness strong growth on consistent expansion of MyoSure suite of products, stability in NovaSure and growing international business.
Hologic has been gaining investors’ confidence on the back of consistent positive results. Over the past three months, Hologic has been outperforming its industry. The stock has lost 1.7% compared with the 5.5% decline of the industry.
Zacks Rank & Key Picks
Hologic currently carries a Zacks Rank #3 (Hold).
A few better-ranked stocks in the broader medical space are Amedisys, Inc (AMED - Free Report) , Intuitive Surgical (ISRG - Free Report) and Inogen, Inc. (INGN - Free Report) .
Amedisys’s expected long-term earnings growth rate is 18.9%. The stock sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Intuitive Surgical’s long-term expected earnings growth rate is 14.7%. The stock carries a Zacks Rank #2 (Buy).
Inogen’s long-term expected earnings growth rate is 24.5%. The stock carries a Zacks Rank #2.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>